Allergan Fortifies Defenses In Response To Valeant’s Hostile Bid
This article was originally published in The Gray Sheet
Executive Summary
Allergan’s board adopted a so-called poison pill stockholder rights plan to hold off Valeant’s hostile takeover effort while it reviews the unsolicited offer.
You may also be interested in...
Allergan To Sell Lap-Band Franchise To Apollo For Up To $110 Million
The firm announced Oct. 29 an agreement with Apollo Endosurgery to sell its obesity intervention business, including the Lap-Band adjustable band.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.